Ascendis Pharma A/SASNDEarnings & Financial Report
Growth hormone therapy refers to the use of growth hormone (GH) as a prescription medication—it is one form of hormone therapy. Growth hormone is a peptide hormone secreted by the pituitary gland that stimulates growth and cell reproduction. In the past, growth hormone was extracted from human pituitary glands. Growth hormone is now produced by recombinant DNA technology and is prescribed for a variety of reasons. GH therapy has been a focus of social and ethical controversies for 50 years.
ASND Q4 2025 Key Financial Metrics
Revenue
$267.3M
Gross Profit
$241.8M
Operating Profit
N/A
Net Profit
N/A
Gross Margin
90.5%
Operating Margin
N/A
Net Margin
N/A
YoY Growth
42.3%
Financial Flow
Ascendis Pharma A/S Q4 2025 Financial Summary
Ascendis Pharma A/S reported revenue of $267.3M (up 42.3% YoY) for Q4 2025, with a net profit of N/A (N/A margin). Cost of goods sold was $25.5M.
Key Financial Metrics
| Total Revenue | $267.3M |
|---|---|
| Net Profit | N/A |
| Gross Margin | 90.5% |
| Operating Margin | N/A |
| Report Period | Q4 2025 |
Ascendis Pharma A/S Annual Revenue by Year
Ascendis Pharma A/S annual revenue history includes year-by-year totals (for example, 2025 revenue was $777.7M). Click any linked year to see what changed vs the prior 10-K.
Ascendis Pharma A/S Quarterly Revenue & Net Profit History
Ascendis Pharma A/S quarterly results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 2025 | $267.3M | +42.3% | N/A | N/A |
| Q3 2025 | $230.7M | +269.4% | $-65.9M | -28.5% |
| Q2 2025 | $170.7M | +339.0% | $-42.0M | -24.6% |
| Q1 2025 | $109.0M | +5.3% | $-102.2M | -93.7% |
| Q4 2024 | $187.8M | +26.3% | N/A | N/A |
| Q3 2024 | $62.5M | +20.4% | $-107.1M | -171.5% |
| Q2 2024 | $38.9M | -24.0% | $-118.1M | -303.9% |
| Q1 2024 | $103.6M | +185.5% | $-141.5M | -136.6% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $103.6M | $38.9M | $62.5M | $187.8M | $109.0M | $170.7M | $230.7M | $267.3M |
| YoY Growth | 185.5% | -24.0% | 20.4% | 26.3% | 5.3% | 339.0% | 269.4% | 42.3% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $866.7M | $819.0M | $1.18B | $1.27B | $1.15B | $1.17B | $1.25B | $1.41B |
| Liabilities | $1.12B | $1.17B | $1.29B | $1.39B | $1.35B | $1.38B | $1.44B | $1.58B |
| Equity | $-257.2M | $-346.8M | $-105.1M | $-114.2M | $-205.0M | $-202.6M | $-188.0M | $-175.8M |
Cash Flow
| Q1 2024 | Q4 2024 | Q1 2025 | Q4 2025 | |
|---|---|---|---|---|
| Operating CF | $-109.7M | $-330.7M | $-15.5M | $58.2M |